Summary

ICON plc is a global leader in clinical research and healthcare intelligence, founded in Dublin, Ireland in 1990. As one of the world's largest contract research organizations (CROs), ICON provides comprehensive outsourced development services to pharmaceutical, biotechnology, and medical device companies worldwide. The company operates in 55 countries with approximately 41,900 employees, offering end-to-end solutions that span the entire product development lifecycle. ICON's service portfolio includes clinical research services, adaptive trials, biosimilars, commercialization and outcomes consulting, medical imaging, laboratory services, and strategic support for traditional and digital health technologies. The company specializes in therapeutic areas such as oncology, cardiovascular diseases, central nervous system disorders, rare diseases, and women's health. With its 2021 acquisition of PRA Health Sciences, ICON significantly expanded its capabilities and market position, becoming a dominant force in the global CRO industry. The company is publicly traded on NASDAQ under the ticker ICLR and reported $8.28 billion in revenue for 2024.

Job description

What You Will Do

Country strategy and feasibility assessment

Lead country selection strategy developing data-driven recommendations on country mix, site allocation, and enrollment distribution
Oversee CRO completion of design and execution of feasibility assessments including protocol-specific feasibility questionnaires, competitive landscape and trial-density analyses, epidemiology and standard-of-care review, and regulatory and start-up timeline mapping by country
Pressure-test enrollment assumptions by triangulating internal performance data, external intelligence sources, and direct site and investigator input

Site identification and selection

Build and maintain a curated, indication-specific site and investigator landscape across North America, Europe, Asia-Pacific, and Latin America, including academic centers, specialty networks, and high-performing private practices
Lead site identification and qualification, coordinating with CRO partners to run pre-study assessments and translating findings into transparent, criteria-based selection recommendations
Track and manage site performance history — enrollment rates, data quality, inspection and audit history, screen-failure patterns, and startup cycle times — and feed that history into future selection decisions

Data, intelligence, and reporting

Maintain feasibility metrics and enrollment
Present feasibility findings, trade-offs, and recommendations clearly— including where the data is thin and what assumption is carrying the risk

Cross-functional and vendor partnership

Serve as the feasibility point of contact for assigned programs, partnering with study teams from concept through first-patient-in
Manage feasibility and site intelligence vendors and CRO feasibility teams — setting scope, holding quality and timeline standards, and reviewing deliverables critically
Partner with Patient Advocacy and Recruitment on patient-finding, referral pathway, and site-support strategies for indications where the eligible population is scarce or highly competed

Your Profile

Bachelor’s degree in life sciences, nursing, public health, or a related field
5+ years of clinical operations experience in biotech, pharma, or CRO, with extensive experience in country and site feasibility oversight
Therapeutic experience: Experience in Immunology highly preferred (dermatology, GI - nice to have)
Demonstrated ownership of country selection and/or site selection recommendations for global studies, with the analytical work to support them
Strong quantitative skills — comfortable building enrollment models and country scorecards in Excel and working with trial-landscape and real-world data platforms (e.g., Citeline/Informa, IQVIA, TriNetX, ClinicalTrials.gov, EU CTIS)
Working knowledge of ICH GCP, global regulatory and start-up requirements, and country-level submission and approval timelines
Excellent written and verbal communication — able to turn ambiguous data into a clear, defensible recommendation for a senior audience
Ability to manage multiple studies and shifting priorities in a fast-moving, lean organization

Requirements

Bachelor’s degree in life sciences, nursing, public health, or a related field
5+ years of clinical operations experience in biotech, pharma, or CRO
Extensive experience in country and site feasibility oversight
Experience in Immunology highly preferred
Demonstrated ownership of country selection and/or site selection recommendations for global studies
Strong quantitative skills — building enrollment models and country scorecards in Excel
Working with trial-landscape and real-world data platforms (e.g., Citeline/Informa, IQVIA, TriNetX, ClinicalTrials.gov, EU CTIS)
Working knowledge of ICH GCP, global regulatory and start-up requirements, and country-level submission and approval timelines
Excellent written and verbal communication
Ability to manage multiple studies and shifting priorities

Benefits

Competitive base salary
Performance incentives
Medical, Dental & Vision
Retirement plans
Pension plans
Life assurance
Disability coverage
Employee assistance programs
Wellbeing resources
Learning and development

Company overview

ICON plc is a global leader in clinical research and healthcare intelligence, founded in Dublin, Ireland in 1990. As one of the world's largest contract research organizations (CROs), ICON provides comprehensive outsourced development services to pharmaceutical, biotechnology, and medical device companies worldwide. The company operates in 55 countries with approximately 41,900 employees, offering end-to-end solutions that span the entire product development lifecycle. ICON's service portfolio includes clinical research services, adaptive trials, biosimilars, commercialization and outcomes consulting, medical imaging, laboratory services, and strategic support for traditional and digital health technologies. The company specializes in therapeutic areas such as oncology, cardiovascular diseases, central nervous system disorders, rare diseases, and women's health. With its 2021 acquisition of PRA Health Sciences, ICON significantly expanded its capabilities and market position, becoming a dominant force in the global CRO industry. The company is publicly traded on NASDAQ under the ticker ICLR and reported $8.28 billion in revenue for 2024.